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of schizophrenia who were continuously enrolled with pharmacy coverage for 
12-months before treatment initiation. Patients with a diagnosis of bipolar, 
epilepsy or migraine were excluded. The AP cohort was identified by the first 
prescription fill with no prior use in previous 12-months. The combination 
therapy cohort (V+AP) was identified by the first prescription fill for V and an AP 
fill within 30 days. Multivariate survival analysis was used to follow patients to 
first adverse event or up to six years after index date to assess relative risk of 
adverse events. RESULTS: The study population included 1,348 patients treated 
with V+AP (female=52.6%, age=79.3 (± 6.9); history: liver disorder=5.9%, 
congestive heart failure=28.5%, peripheral arterial disease=32.2%) and 1,348 AP 
only patients (female=50.3%, age=79.1 (± 6.8); history: liver disorder=14.3%, 
congestive heart failure=27.9%, peripheral arterial disease=34.3%). Patients 
treated with AP only had a significantly lower risk of cerebrovascular disease 
(HR=0.65, 95% CI: 0.51-0.85, p=0.01) after controlling for potential confounders. 
Adding V did not increase risk of other outcomes evaluated. CONCLUSIONS: 
Clinical trials have failed to provide evidence of the efficacy of V as an adjunct 
therapy to AP to treat schizophrenia, but “off-label” prescribing of V+AP remains 
high. This study provides new evidence to inform prescribing practices in elderly 
patients with schizophrenia. The increased risk of stroke must be weighed 
against any incremental benefit to the patient that the addition of V may 
provide.  
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OBJECTIVES: Antipsychotic medications are extensively used in nursing homes 
for management of behavioral and psychiatric disorders in the elderly. Prior 
research suggests that pneumonia is one of the common causes of 
antipsychotic-related mortality in this population. None of the studies compared 
typical and atypical antipsychotics with respect to pneumonia. This study 
examined the risk of pneumonia with use of typical versus atypical 
antipsychotics in dual eligible elderly nursing home residents. METHODS: The 
study involved a retrospective cohort design matched on propensity score using 
Medicare and Medicaid Analytical eXtract (MAX) data from four US states. The 
study population included elderly dual eligible (Medicaid and Medicare) nursing 
home residents (aged > 65 years) who initiated antipsychotics anytime during 
July 1, 2001 and December 31, 2003. The risk of pneumonia during the 6-month 
follow-up period was modeled using Cox proportional model and extended Cox 
hazard model stratified on matched pairs based on propensity scores, using 
atypical agents as the reference category. RESULTS: Analysis of Medicaid-
Medicare data revealed that there were 49,904 antipsychotic (46,293 atypical and 
3,611 typical) users in the unmatched cohort and 7,218 (3,609 atypical and 3,609 
typical) users in the matched cohort. The unadjusted rate of pneumonia was 
8.17% (295) for atypical users and 5.21% (188) for typical users. The results of Cox 
regression [average Hazards Ratio, HR, 1.24; 95% CI, 0.94-1.64] and extended 
regression [<50 days: HR, 1.17; 0.83-1.66 and 50-180 days: HR, 1.36; 0.87-2.14] 
suggest that, there was no difference in risk of pneumonia among typical  
and atypical users. CONCLUSIONS: The study found no differential risk  
of pneumonia among typical versus atypical antipsychotic use in dual eligible 
nursing home residents. Given the differential risk of mortality with typical  
and atypical use in nursing homes, more research is needed to evaluate  
other contributory factors of mortality with respect to these two antipsychotic 
classes.  
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OBJECTIVES: Despite depression as the most frequent neuropsychiatric 
consequence of stroke, empirical safety evidence of antidepressant use in post-
stroke patients is absent. This study aimed to assess the risk of recurrent stroke 
by antidepressant use among patients with first-ever stroke. METHODS: A 
nested case-control study was performed among patients with first stroke 
analyzing data extracted from the National Health Insurance Research Database 
between 01/01/2000 and 12/31/2008. Cases identified as patients with recurrent 
stroke were individually matched with up to two randomly-selected controls by 
age, sex, and cohort entry date using an incidence density sampling approach. 
Conditional logistic regression was employed to estimate the recurrent stroke 
risk associated with selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TCAs) and “other antidepressants”, as well as to assess the 
impact of dose, duration and recency of antidepressant therapy. RESULTS: The 
study cohort comprised 24,107 patients with first stroke, in which 4,415 cases 
were identified and matched to 8,294 randomly-selected controls. There was no 
statistically increased risk for any use of SSRIs (adjusted odds ratio [OR] = 0.99; 
95% CI, 0.78-1.26), TCAs (adjusted OR = 1.12; 95% CI, 0.96-1.30), or “other 
antidepressants” (adjusted OR = 1.10; 95% CI, 0.90-1.34). The insignificant risk for 
SSRIs remained regardless of varying dose, duration and recency of the therapy. 
However, short-term use of TCAs (≤ 30 days), discontinued TCA therapy in the 1-
30 days and 31-90 days preceding the index date was related to a 1.22-fold (95% 
CI, 1.01-1.49), 1.71-fold (95% CI, 1.18-2.48) and 1.50-fold (95% CI, 1.03-2.20) 
increased risk, respectively. The increased risk by use of “other antidepressants” 
was confined to short-term use (≤ 30 days; adjusted OR = 1.40; 95% CI, 1.07-1.81). 
CONCLUSIONS: Discontinued TCA therapy, short-term use of TCAs and “other 
antidepressants” all increase the recurrent stroke risk in post-stroke patients, 
which warrants clinical vigilance.  
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OBJECTIVES: To assess the clinical and treatment characteristics as well as 
economic burden of anxiety patients in the U.S. veteran population. METHODS: 
A retrospective analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with anxiety were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 300.xx. Comorbid condition status was examined for the 12-
month baseline period before disease identification, and treatment patterns 
were examined for the period between the disease identification date and 60 
days after the identification date. Health care utilization and costs were 
measured in the 12-month follow-up period. RESULTS: A total of 687,325 
patients were diagnosed with anxiety. Common comorbidities included 
hypertension (n=165,086, 24.02%), depressive disorder (n=99,736, 14.51%), post-
traumatic stress disorder (n=92,514, 13.46%) and diabetes (n=89,041, 12.95%). The 
top treatments were simvastatin (n=139,001, 20.22%), citalopram hydrobromide 
(n=118,280, 17.21%), omeprazole (n=112,032, 16.30%), and lisinopril (n=103,489, 
15.06%). Other available treatments were trazodone, sertraline hydrochloride, 
lorazepam, hydrochlorothiazide and aspirin. The numbers of anxiety patients 
with inpatient, outpatient and pharmacy visits were 136,109 (19.80%), 686,307 
(99.85%) and 649,999 (94.57%), respectively, and related costs were $6,586 
(standard deviation [SD]=$32,770), $8,831 (SD=$12,369) and $1,576 (SD=$10,109). 
CONCLUSIONS: U.S. veterans diagnosed with anxiety frequently experienced 
comorbidities such as hypertension, depressive disorder, post-traumatic stress 
disorder, and diabetes in the 1-year baseline period. Future treatment regimen 
choices may need to address anxiety within the context of these comorbidities.  
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OBJECTIVES: To investigate the outcomes of patients with schizophrenia who 
lacked symptomatic control with conventional antipsychotics who were 
switched to olanzapine. METHODS: A post-hoc analysis was conducted on the 
China subgroup (n=475) of a multi-country, 12-month, prospective, non-
interventional observational study. Outcome measures included: Brief 
Psychiatric Rating Scale (BPRS), Clinical Global Impressions-Severity (CGI-S), 
Abnormal Involuntary Movements Scale (AIMS) and the brief WHO-Quality of 
Life Scale (WHO-QoL-BREF). Mixed models for repeated measures controlling for 
baseline scores, gender, age, baseline weight, and investigator were used to 
assess outcomes. RESULTS: Mean baseline CGI-S was 5.02 (95% C.I.: 4.94, 5.11). 
Most patients responded to olanzapine - 97% (95% C.I.: 94%, 98%) defined as a 
reduction in BPRS total score at endpoint by ≥30% relative to baseline. Significant 
improvements were observed in clinical status. LsMean change in BPRS total at 
month 12 from baseline was -33.3 (95% C.I.: -33.9, -32.8), and -3.4 for CGI-S (95% 
C.I.: -3.5, -3.3). Quality of life improved significantly for all domains of the WHO 
QoL-BREF. LsMean changes (improvements) from baseline to month 12 were: 
Physical 26.1(95% C.I.: 25.1, 27.2), Psychological 28.9 (95% C.I.: 27.6, 30.2), Social 
26.1 (95% C.I.: 24.5, 27.6) and Environment 24.3 (95% C.I.: 23.0, 25.6). Mean 
olanzapine dose at endpoint was 7.6mg (range 2.5, 25.0mg). AIMS score 
decreased from 3.9 to 0.3 (p<.0001) over the course of the study. Olanzapine 
treatment was associated with a mean weight gain of 4.2kg (95% C.I.:3.8, 4.6), and 
43% (95% C.I.: 38%, 48%) gained ≥7% of their baseline weight over 12 months. 
CONCLUSIONS: This post-hoc analysis suggests that for patients from mainland 
China with schizophrenia who are still symptomatic, despite previous treatment 
with conventional antipsychotics, switching to olanzapine may result in 
additional benefits in terms of further improvement in symptoms and quality of 
life, and a reduction in abnormal involuntary movements.  
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OBJECTIVES: The goal of this study was to evaluate the efficacy and safety of 
armodafinil as an adjunctive therapy for major depression associated with 
bipolar I disorder. METHODS: Patients 18-65 years of age with bipolar I disorder 
currently experiencing a major depressive episode while taking 1 or 2 mood 
stabilizer(s) and/or second-generation antipsychotics were randomized. The 
primary outcome was the mean change from baseline to week 8 in the 30-item 
Inventory of Depressive Symptomatology–Clinician-rated (IDS-C30) total score. 
RESULTS: 433 patients were randomized (n=199 placebo, n=201 armodafinil 150 
mg, n=33 armodafinil 200 mg). Randomization to the 200 mg armodafinil group 
